NDLI: IL-12 augments antitumor responses to cycled chemotherapy.

Please wait, while we are loading the content...

Year: 2017 Volume: 40

Year: 2016 Volume: 39

Year: 2015 Volume: 38

Year: 2015 Volume: 38 Issue: 9

Year: 2015 Volume: 38 Issue: 8

Year: 2015 Volume: 38 Issue: 7

Year: 2015 Volume: 38 Issue: 6

Year: 2015 Volume: 38 Issue: 5

Year: 2015 Volume: 38 Issue: 4

IL-12 augments antitumor responses to cycled chemotherapy.

Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.

Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.

Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.

Year: 2015 Volume: 38 Issue: 3

Year: 2015 Volume: 38 Issue: 2

Year: 2015 Volume: 38 Issue: 1

Year: 2014 Volume: 37

Year: 2013 Volume: 36

Year: 2012 Volume: 35

Year: 2011 Volume: 34

Year: 2010 Volume: 33

Year: 2009 Volume: 32

Year: 2008 Volume: 31

Year: 2007 Volume: 30

Year: 2006 Volume: 29

Year: 2005 Volume: 28

Year: 2004 Volume: 27

Year: 2003 Volume: 26

Year: 2002 Volume: 25

Year: 1997 Volume: 20

IL-12 augments antitumor responses to cycled chemotherapy.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Zhang, Lingbing Feng, Dongdong Hu, Yingbin Tsung, Kangla Norton, Jeffrey A.
Description	Country affiliation: Canada Author Affiliation: Zhang L ( Department of Surgery, Stanford University School of Medicine, Stanford, CA.)
Abstract	Loss of antitumor response to repeated chemotherapy is a major cause of treatment failure in cancer patients. The development of acquired drug resistance is thought to come primarily from changes in tumor cells, and not host response to the tumor. Our recent study shows that antitumor immunity is activated and contributes significantly to the efficacy of chemotherapy. In this study of mouse tumor models, we demonstrate that loss of antitumor response during multiple cycles of chemotherapy is associated with a lack of immune activation, and not intrinsic tumor cell drug resistance. More importantly, we show that adding interleukin-12 (IL-12) to cycled chemotherapy maintains and even increases antitumor immune response in both immunogenic and nonimmunogenic murine tumors and significantly prolongs survival. In some instances, larger tumor burdens that relapse following an initial cycle of cyclophosphamide and IL-12 are eradicated by subsequent cycles of the same treatment at the same doses. Further analysis demonstrates that the initial cycle of the combined therapy increases antitumor immunity of the host. In other mice when tumors are not eradicated by the current cycle of therapy, it serves as a starting point for the subsequent cycles of treatment to generate higher levels of antitumor immunity and greater antitumor response. These results show that the status of host antitumor immunity is a critical factor affecting antitumor efficacy during repeated administration of chemotherapy. Further, IL-12 augments the antitumor immune response under such conditions.
File Format	HTM / HTML
ISSN	15249557
Issue Number	4
Volume Number	38
e-ISSN	15374513
Journal	Journal of Immunotherapy
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2015-05-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Immunology Discipline Therapeutics Adjuvants, Immunologic Administration & Dosage Cyclophosphamide Drug Resistance, Neoplasm Immunology Interleukin-12 Neoplasms Drug Therapy Animals Cell Line, Tumor Cytotoxicity, Immunologic Drug Effects Female Humans Immunity, Cellular Interferon-gamma Metabolism Mice Mice, Inbred Balb C Mice, Inbred C57bl Neoplasm Transplantation Recurrence Journal Article
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Cancer Research Immunology Pharmacology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in